Biohaven Ltd. (NYSE:BHVN) Director Purchases $996,369.00 in Stock

Biohaven Ltd. (NYSE:BHVN - Get Free Report) Director John W. Childs bought 32,700 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was bought at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This represents a 1.43 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Biohaven Stock Performance

NYSE BHVN opened at $31.12 on Wednesday. The firm has a market capitalization of $3.15 billion, a price-to-earnings ratio of -3.31 and a beta of 1.27. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21. The company's 50 day moving average price is $38.16 and its 200 day moving average price is $42.71.

Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). Sell-side analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Institutional Trading of Biohaven

Several large investors have recently bought and sold shares of the company. Point72 Asset Management L.P. boosted its position in Biohaven by 745.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock valued at $74,969,000 after buying an additional 1,322,922 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Biohaven by 144.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock worth $73,922,000 after purchasing an additional 1,169,721 shares during the last quarter. Norges Bank acquired a new stake in shares of Biohaven during the fourth quarter worth approximately $33,711,000. Farallon Capital Management LLC raised its holdings in Biohaven by 21.6% in the fourth quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company's stock valued at $165,392,000 after acquiring an additional 785,578 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Biohaven by 12.1% during the 4th quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company's stock worth $260,735,000 after acquiring an additional 756,032 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective on shares of Biohaven in a report on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. TD Cowen increased their price objective on shares of Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Biohaven in a research report on Tuesday, February 11th. They set a "buy" rating and a $65.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $54.00 price target on shares of Biohaven in a research report on Tuesday. Fourteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $62.77.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.